When is Tecentriq used for breast cancer?
TECENTRIQ may be used with the medicine paclitaxel protein-bound when your breast cancer: The approval of TECENTRIQ in these patients is based on a study that measured the amount of time until patients’ disease worsened. Continued approval for this use may depend on the results of an ongoing study to confirm benefit.
When should I Call my doctor if I am taking Tecentriq?
Call or see your healthcare provider right away if you get any symptoms of the following problems or these symptoms get worse. TECENTRIQ can cause serious side effects, including: Lung problems (pneumonitis)–signs and symptoms of pneumonitis may include new or worsening cough, shortness of breath, and chest pain.
What are the side effects of Tecentriq?
The most common side effects of TECENTRIQ when used alone include: 1 feeling tired and weak 2 nausea 3 cough 4 shortness of breath 5 decreased appetite
See more
Is Tecentriq covered by insurance?
To be eligible for free TECENTRIQ from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have exhausted all other forms of patient assistance (including the Genentech Oncology Co-pay Program and support from independent co-pay assistance foundations) and must meet certain ...
What is the Genentech Patient Foundation?
The Genentech Patient Foundation gives free Genentech medicine to people who don't have insurance coverage or who have financial concerns.
What drugs does Genentech make?
Our Medicines & ProductsMedicines.Actemra® (TOCILIZUMAB [authorized for Emergency Use])Actemra® (tocilizumab)Activase® (alteplase)Alecensa® (alectinib)Avastin® (bevacizumab)Boniva Tablets® (ibandronate sodium)Cathflo Activase® (alteplase)More items...
What is Genentech famous?
Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.
Who acquired Genentech?
Roche Holding'sRoche Holding's agreement on Thursday to acquire full ownership of Genentech for $46.8 billion is the third big drug industry merger this year.
Where is Genentech headquarters?
South San Francisco, CAGenentech / HeadquartersGenentech's corporate headquarters are in South San Francisco, California (37.657°N 122.379°W), with additional manufacturing facilities in Vacaville, California; Oceanside, California; and Hillsboro, Oregon.
Who started Genentech?
Robert A. SwansonHerbert BoyerGenentech/Founders
Coverage
Help understanding benefits and coverage, such as benefits investigations and prior authorization resources
Product Distribution
A list of authorized distributors and specialty pharmacies as well as information on our Spoilage Replacement Program
How to contact Genentech?
Ask about possible side effects and any other medical questions related to your prescribed Genentech medicine. Call us at (800) 821-8590, Monday-Friday, 5am-5pm PT. Chat with us using our live chat feature, Monday-Friday, 5am-5pm PT. Email us by filling out this form. RESOURCES.
What is the phone number for Genentech?
Call us at (877) 436-3683 or (877) GENENTECH, Monday-Friday, 6am-5pm PT. This service offers coverage support, patient assistance, and other useful information. Provides free medicine to patients without insurance coverage or who can't pay for their Genentech medicine. Provides additional resources and information.
How to report Tecentriq side effects?
Report side effects for your Tecentriq prescription. Report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. Get help paying for your Tecentriq prescription. SUPPORT.
How long after tecentriq is breastfed?
are breastfeeding or plan to breastfeed. It is not known if TECENTRIQ passes into your breast milk. Do not breastfeed during treatment and for at least 5 months after the last dose of TECENTRIQ.
What is a TNBC?
A type of breast cancer called triple-negative breast cancer (TNBC). TECENTRIQ may be used with the medicine paclitaxel protein-bound when your breast cancer: has spread or cannot be removed by surgery, and. your cancer tests positive for “PD-L1.”.
What is a tecentriq?
TECENTRIQ is a prescription medicine used to treat adults with: A type of bladder and urinary tract cancer called urothelial carcinoma. TECENTRIQ may be used when your bladder cancer has spread or cannot be removed by surgery, and if you have any one of the following conditions:
How to report a tecentriq?
Ask your healthcare provider or pharmacist for more information about the benefits and side effects of TECENTRIQ. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
What is a tecentriq access solution?
TECENTRIQ Access Solutions can refer you to the Genentech Oncology Co-pay Assistance Program. It can help you with the out-of-pocket costs of your Genentech medicine, if you’re eligible.*
Who provides Genentech medicine?
The Genentech Patient Foundation provides free Genentech medicine to people who don't have insurance coverage or who have financial concerns and to people who meet certain income criteria.*
What is Genentech copay?
The Genentech Oncology Co-pay Program helps people with commercial health insurance. This might be a plan you get through your employer or one you purchased through a Health Insurance Marketplace like HealthCare.gov. To qualify, you must also meet other criteria.
How to get patient consent form for Genentech?
Once we have both forms, we can begin working with you and your doctor's office. You can find the Patient Consent Form at Genentech-Access.com/PatientConsent or your doctor might give it to you.
Who gives free tecentriq?
The Genentech Patient Foundation gives free TECENTRIQ to people who don't have insurance coverage or who have financial concerns.
Does Genentech have copay assistance?
If you need help with the co-pay for your Genentech medicine, Genentech Oncology Access Solutions for TECENTRIQ can refer you to an independent co-pay assistance foundation. Independent co-pay assistance foundations help patients with public or commercial health insurance.
How to contact Genentech about Tecentriq?
SUPPORT. Medicine Information Support. Medical information about Genentech medicines. Call us at (800) 821-8590, Monday-Friday, 5am-5pm PT. Request a Call Back. Request an Office Visit with a Medical Science Liaison.
What is the number for Genentech?
Genentech Patient Resource Center. Our center dedicated to getting patients and caregivers to the right resources. Call us at (877) 436-3683 or (877) GENENTECH, Monday-Friday, 6am-5pm PT. Genentech Access Solutions. This service offers your patients coverage support, assistance, and other useful information.
How long does it take for tecentriq to taper?
In general, if TECENTRIQ requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less, then initiate corticosteroid taper and continue to taper over at least 1 month.
What are the adverse reactions of tecentriq?
The most common adverse reactions (rate ≥20%) in patients who received TECENTRIQ in combination with other antineoplastic drugs for NSCLC and SCLC were fatigue/asthenia (49%), nausea (38%) , alopecia (35%), constipation (29%), diarrhea (28%), and decreased appetite (27%).
What is tecentriq used for?
TECENTRIQ, in combination with bevacizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Can tecentriq cause adrenal insufficiency?
TECENTRIQ can cause primary or secondary adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated
Is tecentriq a single agent?
TECENTRIQ, as a single agent, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1–stained ≥50% of tumor cells [TC ≥50%] or PD-L1–stained tumor-infiltrating immune cells [IC] covering ≥10% of the tumor area [IC ≥10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
